The company has significantly advanced its development of an new therapy for cardiac amyloidosis, utilizing the investigational drug. Early trial data reveals significant outcomes for individuals suffering by a debilitating illness. This focus represents the company’s commitment to addressing significant healthcare demands in a heart disease fiel